Abstract
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Current Pharmaceutical Design
Title:The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer
Volume: 27 Issue: 39
Author(s): Wen Xu, Bei Wang, Yuxuan Cai, Jinlan Chen, Enqing Meng, Chong Guo, Gang Zhou*Chengfu Yuan*
Affiliation:
- College of Traditional Chinese Medicine, China Three Gorges University, Yichang 443002,China
- College of Medical Science, China Three Gorges University, Yichang 443002,China
Keywords: Long non-coding RNA, FENDRR, cancer, biomarkers, therapeutic targets, clinical prognosis.
Abstract:
Background: Long noncoding RNA (lncRNA) fetal-lethal non-coding developmental regulatory RNA (FENDRR), a newly known lncRNA, has been reported to be abnormally expressed in diverse tumors. This review is focused on clarifying the mechanism of FENDRR to regulate the biological process of tumors, affirming its value as a target for tumor therapy.
Methods: The pathophysiological mechanism of FENDRR acting on tumors has been analyzed and summarized by reviewing PubMed.
Results: The expression of lncRNA FENDRR is abnormally altered in clinical cancers, promoting the malignant transformation of a variety of tumors, including colon cancer, cervical cancer, hepatocellular carcinoma, prostate cancer, Malignant melanoma, lung cancer, osteosarcoma, breast cancer, etc. Cellular processions, including proliferation, invasion, apoptosis and migration affected by FENDRR, have been revealed.
Conclusion: Specific evidences for the involvement of LncRNA FENDRR in cancer regulatory processes suggest that FENDRR has the potential to be a biomarker or clinical therapeutic target for malignant tumors.
Export Options
About this article
Cite this article as:
Xu Wen , Wang Bei , Cai Yuxuan , Chen Jinlan, Meng Enqing, Guo Chong , Zhou Gang *, Yuan Chengfu *, The Therapeutic Value and Molecular Mechanisms of lncRNA FENDRR in Human Cancer, Current Pharmaceutical Design 2021; 27 (39) . https://dx.doi.org/10.2174/1381612827666210820094702
DOI https://dx.doi.org/10.2174/1381612827666210820094702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melanoma
Current Cancer Therapy Reviews EGFR Inhibitors and Radiation in HNSCC
Current Cancer Therapy Reviews Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology In Silico Screening of Novel Inhibitors for HPV: A Rational Structure Based Approach (Docking Versus Pharmacophore Model Generation)
Letters in Drug Design & Discovery Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Infectious Disorders - Drug Targets Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews In Silico and In Vitro Analysis of a Multiepitope L1-E7 Fusion Construct for Vaccine Development Against Human Papillomaviruses
Letters in Drug Design & Discovery Uncommon Becoming Common: Case Series of Primary Fallopian Tube Cancers
Current Women`s Health Reviews Resveratrol Regulates Nrf2-Mediated Expression of Antioxidant and Xenobiotic Metabolizing Enzymes in Pesticides-Induced Parkinsonism
Protein & Peptide Letters Oncogene Suppression by Small Interfering RNAs
Current Pharmaceutical Biotechnology Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics
Combinatorial Chemistry & High Throughput Screening MicroRNAs as Cancer Biomarkers
MicroRNA